Mega Genomics Ltd. has announced a delay in the publication of its 2024 Annual Results and the associated Annual Report. The company, listed on the Hong Kong Stock Exchange, stated that the delay is due to ongoing discussions with a potential new auditor. Trading in the company's shares has been suspended since April 1, 2025, and will remain so until further notice. The company aims to dispatch the necessary Circular to shareholders as soon as practicable.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。